ClinicalTrials.gg
Sign In
Not yet recruitingNCT07875842Updated Oct 15, 2026

A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults

A Phase 1 interventional study of Itraconazole and Rifampicin in Healthy Subjects, sponsored by InventisBio Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Other

Updated Oct 15, 2026Newly registeredGo to Updates ↓
Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary purpose of this study is to characterize the drug-drug interaction profiles of D-2570 with midazolam, digoxin, rosuvastatin, metformin, itraconazole, rifampicin, and omeprazole.

Read the detailed description

The drug-drug interaction study is meant to evaluate the pharmacokinetics and safety of D-2570 tablet combined Midazolam, Digoxin,Rosuvastatin and Metformin, Itraconazole, Rifampicin and Omeprazole in Healthy Trial Participants

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse InventisBio Co., Ltd studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • After full informed consent, voluntarily participate in this study and sign the written Informed Consent Form (ICF), and agree to abide by the procedures specified in the study protocol;
  • No pregnancy, sperm donation or egg donation plan from the start of screening to 30 days after the last administration of investigational product, and agree to completely abstain from sexual activity or adopt effective contraceptive measures throughout the period from screening to 30 days after the last administration of investigational product;
  • Male or female trial participants aged 18 to 45 years old (inclusive of 18 and 45 years old);
  • Male trial participants weigh no less than 50 kg, female trial participants weigh no less than 45 kg. Body Mass Index (BMI) = weight (kg) / height² (m²), and the Body Mass Index is within the range of 19 \~ 26 kg/m² (inclusive of the critical values);
  • Vital signs, physical examination, laboratory tests, electrocardiogram, abdominal color ultrasound (liver, gallbladder, spleen, pancreas, bilateral kidneys) and chest X-ray (anteroposterior view) results are normal, or abnormal findings are judged by the investigator to be clinically insignificant.

Exclusion criteria

Exclusion Criteria:

  • History of herpes zoster or severe herpes simplex, or presence of herpes zoster/herpes simplex during the screening period;
  • Individuals who cannot tolerate venipuncture/indwelling needle blood collection, or have needle phobia and hemophobia;
  • Previously received surgeries that may affect drug absorption, distribution, metabolism and excretion, and are judged by the investigator to be unsuitable for enrollment;
  • Individuals with a history of drug or substance abuse, or with a positive urine drug abuse screening result;
  • Trial participants who have other factors that the investigator considers inappropriate to participate in this trial.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Coadministration of D-2570 Tablets and Itraconazole

    The DDI study of D2570 and Itraconazole

    Drug: Itraconazole · Drug: D-2570

  • Experimental
    Coadministration of D-2570 Tablets and Rifampicin

    The DDI study of D2570 and Itraconazole

    Drug: Rifampicin · Drug: D-2570

  • Experimental
    Coadministration of D-2570 Tablets and Omeprazole

    The DDI study of D2570 and Rifampicin

    Drug: Omeprazole · Drug: D-2570

  • Experimental
    Coadministration of D-2570 tablets and midazolam, digoxin, rosuvastatin, and metformin

    The DDI study of D2570 and midazolam, digoxin, rosuvastatin, and metformin

    Drug: D-2570 · Drug: Midazolam · Drug: Digoxin · Drug: Rosuvastatin · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. The main PK parameters#Maximum observed plasma concentration-Cmax

    The main PK parameters#Maximum observed plasma concentration-Cmax

    Time frame: through study completion, an average of 20 days

  2. The main PK parameters#Area under the plasma concentration versus time curve-AUC

    The main PK parameters#Area under the plasma concentration versus time curve-AUC

    Time frame: through study completion, an average of 20 days

Secondary outcomes

  1. Time to maximum measured plasma concentration -Tmax

    Time to maximum measured plasma concentration -Tmax

    Time frame: through study completion, an average of 20 days

  2. Half-life -t1/2

    Half-life -t1/2

    Time frame: through study completion, an average of 20 days

  3. CL/F (apparent clearance)

    CL/F (apparent clearance)

    Time frame: through study completion, an average of 20 days

  4. Vz/F (apparent volume of distribution)

    Vz/F (apparent volume of distribution)

    Time frame: through study completion, an average of 20 days

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v6.0

    Incidence of adverse events

    Time frame: through study completion, an average of 1 month

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07875842
Lead sponsor
InventisBio Co., Ltd
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Sep 16, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 15, 2026

Study contacts

Huan Zhou, Doctor
Contact
zhouhuanbest@vip.163.com
13665527160
Dingli Yao
Contact
dingli.yao@inventisbio.com
15538261075
Huan Zhou, Doctor
principal investigator · The First Affiliated Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Itraconazole · Rifampin · Omeprazole · D-2570 · Midazolam · Digoxin · Rosuvastatin · Metformin

Other studies from this sponsor

InventisBio Co., Ltd →

Start the discussion